Recipharm, Kancera in Drug Product Pact
By

Recipharm, a Swedish contract development and manufacturing organization, and Kancera, a Swedish biotechnology company focused on cancer therapy, have signed a contract for the development and manufacture of Kancera’s pharmaceutical candidate, KAND567, which is being developed for counteracting the onset of autoimmune disorders, as well as neuritis and pain in connection with chemotherapy against cancer.

As part of the collaboration, Recipharm will develop the preparation that is required for release of KAND567 from capsules as well as manufacturing the pharmaceutical product. The work will be performed at Recipharm’s development facility in Solna, Sweden.

Source: Recipharm

 

Leave a Reply

Your email address will not be published. Required fields are marked *